Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 522 clinical trials
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

multiple myeloma
measurable disease
  • 0 views
  • 31 May, 2021
  • 70 locations
Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003)

The purpose of this study is to evaluate the safety and efficacy of MK-1026 (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small

mantle cell lymphoma
hepatitis b surface antigen
lymphoma
leukemia
measurable disease
  • 0 views
  • 21 Jul, 2021
  • 12 locations
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose (RP2D) (Part 3).

multiple myeloma
measurable disease
  • 0 views
  • 25 Jun, 2021
  • 76 locations
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 [Dose Escalation]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part …

multiple myeloma
measurable disease
human chorionic gonadotropin
  • 65 views
  • 24 Jul, 2021
  • 16 locations
Durvalumab and Tremelimumab for Pediatric Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

cancer
acute leukemia
lymphoma
leukemia
durvalumab
  • 15 views
  • 07 Jul, 2021
  • 25 locations
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had …

hematologic malignancy
solid tumor
metastatic malignant solid tumor
cancer
  • 16 views
  • 24 Jan, 2021
  • 5 locations
TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia

The purpose of this study is to test whether giving tranexamic acid to patients receiving treatment for blood cancers reduces the risk of bleeding or death, and the need for platelet

hematologic malignancy
tranexamic acid
cell transplantation
cancer
  • 682 views
  • 14 Mar, 2021
  • 28 locations
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older Medically Infirm or Frail Patients With Blood Diseases

This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), …

cancer
hematologic disorders
cell transplantation
blood disorder
  • 3 views
  • 14 Jun, 2021
  • 12 locations
Study of Tinostamustine First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive

hodgkin's disease
cancer
leukemia
t-cell lymphoma
multiple myeloma
  • 0 views
  • 14 Jun, 2021
  • 26 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received

hematologic malignancy
IDH2
blast cells
  • 0 views
  • 22 Jul, 2021
  • 47 locations